February 2, 2021 11:29 AM EST

James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6

Jason Mast

Editor

Amber Tong

Senior Editor

James Sabry and Aviv Regev at Roche and Genentech have been racking up early stage partnerships, tying up with early stage biotechs developing everything from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6

Jason Mast

Editor

Amber Tong

Senior Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

James Sabry adds an­oth­er weapon to Roche-Genen­tech ar­se­nal; Dai­ichi Sankyo adds ADC #6

Editor

Senior Editor

Sign up to read this article for free.

James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6